The global pharmaceutical analytical testing outsourcing market size is estimated to reach USD 14.56 billion by 2030 and is projected to grow at a CAGR of 8.6% from 2025 to 2030. Increasing biological candidate pipelines, rising demand for additional analytical details on drugs, and process development by regulatory agencies are driving market growth. Analytical testing aids in real-time product quality control as well as help optimize and monitor processes, thereby identifying different drugs. Over the years, the number of clinical trials has increased consistently.
For instance, in 2021, over 399,525 clinical studies were registered on ClinicalTrial.gov, whereas as of June 2022, it had increased to over 421,258 studies. A continuation of this trend is expected to have a positive impact on the market in the post-pandemic period. The majority of small and medium-sized pharma companies lack the infrastructure for analytical testing. As a result, outsourcing these operations is the best option as it saves time and money. The patent cliff, primarily for small molecules and biologics, is likely to have a positive impact on the market as it will increase the number of commercial drugs in the pharma market, thus promoting the analytical testing of commercially available generic drugs.
There has been a rise in several diseases post-COVID-19. For instance, according to a report published by Children’s National Hospital- pediatric research and clinical innovations center, a study was performed on 737 youths who were diagnosed with diabetes, and it found an increased incidence of pediatric Type 1 Diabetes (T1D) by 15.2% and Type 2 Diabetes (T2D) increased by 182% between March 11, 2018, and March 10, 2021. The rise in disease incidence is expected to improve, drug production, which is likely to drive the demand for analytical services for commercial drugs .
Request a free sample copy or view report summary: Pharmaceutical Analytical Testing Outsourcing Market Report
The bioanalytical testing segment dominated the market, accounting for a revenue share of 38.44% in 2024. Bioanalytical testing covers both clinical and non-clinical studies.
The pharmaceutical segment gained the largest market share in 2024. The growing demand among pharmaceutical companies to focus on their core competencies is one of the major reasons for the largest segment share.
North America is expected to hold the largest revenue share of 52.91% owing to the presence of a significant number of pharmaceutical companies in the region.
Asia Pacific is anticipated to be the fastest-growing regional market from 2025 to 2030 due to the low-cost service offerings by third-party service providers in the region.
Grand View Research has segmented the global pharmaceutical analytical testing outsourcing market report based on service, end use, and region:
Pharmaceutical Analytical Testing Outsourcing Service Outlook (Revenue, USD Million, 2018 - 2030)
Bioanalytical Testing
Clinical
Non-Clinical
Method Development & Validation
Extractable & Leachable
Impurity Method
Technical Consulting
Others
Stability Testing
Drug Substance
Stability Indicating Method Validation
Accelerated Stability Testing
Photostability Testing
Others
Others
Pharmaceutical Analytical Testing Outsourcing End Use Outlook (Revenue, USD Million, 2018 - 2030)
Pharmaceutical Companies
Biopharmaceutical Companies
Contract Research Organizations
Pharmaceutical Analytical Testing Outsourcing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
Thailand
South Korea
Australia
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Pharmaceutical Analytical Testing Outsourcing Market
SGS Société Générale de Surveillance SA
Labcorp
Eurofins Scientific
Pace Analytical Services LLC
Intertek Group plc
Thermo Fisher Scientific Inc.
Wuxi AppTec
BA Sciences
Charles River Laboratories
West Pharmaceutical Services, Inc
"The quality of research they have done for us has been excellent..."